Inflammatory Bowel Disease

Patients with ulcerative colitis who achieve more rigorous treatment endpoints are at lower risk for relapse than patients who only achieve clinical remission, according to study results.

Healio Gastroenterology presents the following reports on the most recent research on inflammatory bowel disease.

The gap between patient-reported outcomes and clinician-assessed endpoints in rheumatology is well documented. Patients generally care about pain, fatigue and the emotional toll immune-mediated diseases can take, while physicians are more likely to pay attention to interleukin activity or C-reactive protein levels.

One in eight patients with inflammatory bowel disease are food insecure and lack social support, according to research published in Clinical Gastroenterology and Hepatology.

Features of inflammatory bowel disease differed between children with primary sclerosing cholangitis and those without it, similar to adult patients, according to study results.

Frailty was independently associated with mortality in a large cohort of patients with inflammatory bowel disease, according to study results.

Zeposia may be an efficacious new oral therapy option with a favorable risk-benefit profile for patients with ulcerative colitis.

Oral curcumin was no more effective than placebo for preventing Crohn’s disease recurrence among patients who underwent surgery for Crohn’s, according to study results.

An analysis presented at Digestive Disease Week showed that patients with late-onset inflammatory bowel disease had a greater recurrence of colorectal cancer than patients with early-onset inflammatory bowel disease. It was the top story in gastroenterology last week.

For patients who underwent ileocolonic resection with ileocolonic anastomosis, high-dose vitamin D did not reduce the incidence of postoperative endoscopic or clinical recurrence of Crohn’s disease, according to recently published results.